CSL Limited
์๊ฐ์ด์ก
$41.9B
๊ธ๋ก๋ฒ ์์
#278
์ญ๋ ์ต๊ณ ์น
$85.2B
2023-12-31
์ด ์ฑ์ฅ๋ฅ
+0%
2026๋ ์ดํ
Market Cap Context
- Larger than 24% of the 367 companies we track (globally).
- Equivalent to 2.3% of Australia's GDP (2025 data).
- Just above: #277 Paychex, Inc. ($42.2B)
- Just below: #279 ITC Limited ($41.1B)
- Best year: 2000 (+80%). Worst year: 2002 (-58%).
CSL Limited Financial Breakdown (FY 2025)
Source: Yahoo Finance โ CSL.AX annual filings (2025) โ$15.4B revenue ยท $3.0B operating income ยท $3.0B net income
- โOperating margin: 19.2% on $15.4B in revenue.
- โR&D is 8.8% of revenue ($1.4B).
- โNet income margin: 19.5% โ $3.0B in profit.
- โFree cash flow: $2.5B (16.5% of revenue).
Cost / Operating Expenses
Total operating expenses $12.5B
Total
$11.5B
Capital Expenditures
$1.0B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$2.5B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
CSL Limited ์๊ฐ
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.
CSL Limited ์๊ฐ์ด์ก ์ถ์ด (2026โ2026)
CSL Limited vs Sector Peers by Market Cap
CSL Limited ๋น๊ต
์์ ์ถ์ด
| ์ฐ๋ | ์๊ฐ์ด์ก | ์์ | ์ ๋ ๋๋น ๋ณํ |
|---|---|---|---|
| 2026 | $41.9B | #278(โ37) | -21.0% |
| 2025 | $53.1B | #241(โ91) | -37.5% |
| 2024 | $84.9B | #150(โ16) | -0.4% |
| 2023 | $85.2B | #134(โ24) | +0.9% |
| 2022 | $84.5B | #110(โ11) | +0.1% |
| 2021 | $84.4B | #121(โ17) | +3.7% |
| 2020 | $81.3B | #104(โ17) | +3.7% |
| 2019 | $78.4B | #87(โ10) | +50.8% |
| 2018 | $52.0B | #97(โ47) | +32.6% |
| 2017 | $39.2B | #144(โ20) | +42.7% |
| 2016 | $27.5B | #164(โ21) | -3.0% |
| 2015 | $28.3B | #143(โ26) | +23.7% |
| 2014 | $22.9B | #169(โ16) | +27.9% |
| 2013 | $17.9B | #185(โ11) | +30.1% |
| 2012 | $13.8B | #174(โ31) | +72.1% |
| 2011 | $8.0B | #205(โ2) | -9.4% |
| 2010 | $8.8B | #207(โ3) | +14.4% |
| 2009 | $7.7B | #204(โ41) | -1.6% |
| 2008 | $7.9B | #163(โ36) | -6.1% |
| 2007 | $8.4B | #199(โ27) | +68.8% |
| 2006 | $5.0B | #226(โ10) | +55.9% |
| 2005 | $3.2B | #236(โ2) | +47.7% |
| 2004 | $2.2B | #238(โ3) | +66.3% |
| 2003 | $1.3B | #241(โ22) | -15.6% |
| 2002 | $1.5B | #219(โ34) | -57.5% |
| 2001 | $3.6B | #185(โ2) | +32.6% |
| 2000 | $2.7B | #187(โ21) | +79.9% |
| 1999 | $1.5B | #166(โ2) | +58.6% |
| 1998 | $954.6M | #168(โ1) | +48.3% |
| 1997 | $643.5M | #169(โ4) | +64.6% |
| 1996 | $391.0M | #165(โ12) | +52.3% |
| 1995 | $256.7M | #153(โ14) | +71.4% |
| 1994 | $149.8M | #139 |
๊ธฐํ ํฌ์ค์ผ์ด ๊ธฐ์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
What is CSL Limited's market cap?
CSL Limited (CSL.AX) has a market capitalization of $41.9B, making it the #278 largest company in the world by market cap.
What was CSL Limited's highest market cap?
CSL Limited's all-time high market cap was $85.2B, reached in 2023-12-31. Its highest rank was #134 in 2023.
What sector is CSL Limited in?
CSL Limited is in the Healthcare sector, specifically the Biotechnology industry. It is based in Australia.
How has CSL Limited's market cap changed over time?
CSL Limited has been tracked since 2026. Its market cap has grown by 0% from $41.9B in 2026 to $41.9B today.